speb/financial-data huggingface dataset:
LAB balance_sheet (quarterly, 2025-12-31) — Construction In Progress: 900000.00
LAB income_statement (annual, 2025-12-31) — Cost Of Revenue: 42788000.00
LAB income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 12413000.00
LAB balance_sheet (annual, 2025-12-31) — Current Accrued Expenses: 10696000.00
LAB balance_sheet (quarterly, 2025-12-31) — Current Accrued Expenses: 10696000.00
LAB balance_sheet (annual, 2025-12-31) — Current Assets: 454264000.00
LAB balance_sheet (quarterly, 2025-12-31) — Current Assets: 454264000.00
LAB balance_sheet (annual, 2025-12-31) — Current Capital Lease Obligation: 5490000.00
LAB balance_sheet (quarterly, 2025-12-31) — Current Capital Lease Obligation: 5490000.00
LAB balance_sheet (annual, 2025-12-31) — Current Debt And Capital Lease Obligation: 5490000.00
LAB balance_sheet (quarterly, 2025-12-31) — Current Debt And Capital Lease Obligation: 5490000.00
LAB balance_sheet (annual, 2025-12-31) — Current Deferred Liabilities: 42936000.00
LAB balance_sheet (quarterly, 2025-12-31) — Current Deferred Liabilities: 42936000.00
LAB balance_sheet (annual, 2025-12-31) — Current Deferred Revenue: 42936000.00
LAB balance_sheet (quarterly, 2025-12-31) — Current Deferred Revenue: 42936000.00
LAB balance_sheet (annual, 2025-12-31) — Current Liabilities: 108308000.00
LAB balance_sheet (quarterly, 2025-12-31) — Current Liabilities: 108308000.00
LAB cash_flow (annual, 2025-12-31) — Depreciation: 9262000.00
LAB cash_flow (quarterly, 2025-12-31) — Depreciation: 1291000.00
LAB cash_flow (annual, 2025-12-31) — Depreciation Amortization Depletion: 10977000.00
LAB cash_flow (quarterly, 2025-12-31) — Depreciation Amortization Depletion: 1291000.00
LAB cash_flow (annual, 2025-12-31) — Depreciation And Amortization: 10977000.00
LAB cash_flow (quarterly, 2025-12-31) — Depreciation And Amortization: 1291000.00
LAB income_statement (annual, 2025-12-31) — Diluted Average Shares: 381623000.00
LAB income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 385048000.00
LAB income_statement (annual, 2025-12-31) — Diluted EPS: -0.20
LAB income_statement (quarterly, 2025-12-31) — Diluted EPS: 0.05
LAB income_statement (annual, 2025-12-31) — Diluted NI Availto Com Stockholders: -74896000.00
LAB income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: 19283000.00
LAB income_statement (annual, 2025-12-31) — EBIT: -96676000.00
LAB income_statement (quarterly, 2025-12-31) — EBIT: -22026000.00
LAB income_statement (annual, 2025-12-31) — EBITDA: -85699000.00
LAB income_statement (quarterly, 2025-12-31) — EBITDA: -20735000.00
LAB cash_flow (annual, 2025-12-31) — Effect Of Exchange Rate Changes: 842000.00
LAB cash_flow (quarterly, 2025-12-31) — Effect Of Exchange Rate Changes: -100000.00
LAB cash_flow (annual, 2025-12-31) — End Cash Position: 123296000.00
LAB cash_flow (quarterly, 2025-12-31) — End Cash Position: 123296000.00
LAB cash_flow (annual, 2025-12-31) — Financing Cash Flow: 570000.00
LAB cash_flow (quarterly, 2025-12-31) — Financing Cash Flow: 620000.00
LAB balance_sheet (annual, 2025-12-31) — Finished Goods: 11097000.00
LAB balance_sheet (quarterly, 2025-12-31) — Finished Goods: 11097000.00
LAB cash_flow (annual, 2025-12-31) — Free Cash Flow: -82646000.00
LAB cash_flow (quarterly, 2025-12-31) — Free Cash Flow: -1666000.00
LAB cash_flow (annual, 2025-12-31) — Gain Loss On Investment Securities: -232000.00
LAB cash_flow (quarterly, 2025-12-31) — Gain Loss On Investment Securities: 0.00
LAB balance_sheet (annual, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: -1492000.00
LAB balance_sheet (quarterly, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: -1492000.00
LAB balance_sheet (annual, 2025-12-31) — Gross Accounts Receivable: 13715000.00
LAB balance_sheet (quarterly, 2025-12-31) — Gross Accounts Receivable: 13715000.00
LAB balance_sheet (annual, 2025-12-31) — Gross PPE: 94169000.00
LAB balance_sheet (quarterly, 2025-12-31) — Gross PPE: 94169000.00
LAB income_statement (annual, 2025-12-31) — Gross Profit: 42543000.00
LAB income_statement (quarterly, 2025-12-31) — Gross Profit: 11382000.00
LAB income_statement (annual, 2025-12-31) — Interest Expense: 26000.00
LAB income_statement (quarterly, 2025-12-31) — Interest Expense: 5000.00
LAB income_statement (annual, 2025-12-31) — Interest Expense Non Operating: 26000.00
LAB income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 5000.00
LAB income_statement (annual, 2025-12-31) — Interest Income: 9179000.00
LAB income_statement (quarterly, 2025-12-31) — Interest Income: 1662000.00
LAB income_statement (annual, 2025-12-31) — Interest Income Non Operating: 9179000.00
LAB income_statement (quarterly, 2025-12-31) — Interest Income Non Operating: 1662000.00
LAB cash_flow (annual, 2025-12-31) — Interest Paid Supplemental Data: 15000.00
LAB cash_flow (quarterly, 2025-12-31) — Interest Paid Supplemental Data: 0.00
LAB balance_sheet (annual, 2025-12-31) — Inventory: 19981000.00
LAB balance_sheet (quarterly, 2025-12-31) — Inventory: 19981000.00
LAB balance_sheet (annual, 2025-12-31) — Invested Capital: 424590000.00
LAB balance_sheet (quarterly, 2025-12-31) — Invested Capital: 424590000.00
LAB cash_flow (annual, 2025-12-31) — Investing Cash Flow: 27409000.00
LAB cash_flow (quarterly, 2025-12-31) — Investing Cash Flow: -8040000.00
LAB balance_sheet (annual, 2025-12-31) — Investments And Advances: 25701000.00
LAB balance_sheet (quarterly, 2025-12-31) — Investments And Advances: 25701000.00
LAB balance_sheet (annual, 2025-12-31) — Leases: 14050000.00
LAB balance_sheet (quarterly, 2025-12-31) — Leases: 14050000.00
LAB balance_sheet (annual, 2025-12-31) — Liabilities Heldfor Sale Non Current: 0.00
LAB balance_sheet (quarterly, 2025-12-31) — Liabilities Heldfor Sale Non Current: 0.00
LAB balance_sheet (annual, 2025-12-31) — Long Term Capital Lease Obligation: 25038000.00
LAB balance_sheet (quarterly, 2025-12-31) — Long Term Capital Lease Obligation: 25038000.00
LAB balance_sheet (annual, 2025-12-31) — Long Term Debt: 299000.00
LAB balance_sheet (quarterly, 2025-12-31) — Long Term Debt: 299000.00
LAB balance_sheet (annual, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 25337000.00
LAB balance_sheet (quarterly, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 25337000.00
LAB balance_sheet (annual, 2025-12-31) — Machinery Furniture Equipment: 17104000.00
LAB balance_sheet (quarterly, 2025-12-31) — Machinery Furniture Equipment: 17104000.00
LAB cash_flow (annual, 2025-12-31) — Net Business Purchase And Sale: 0.00
LAB cash_flow (annual, 2025-12-31) — Net Common Stock Issuance: 0.00
LAB cash_flow (quarterly, 2025-12-31) — Net Common Stock Issuance: 0.00
LAB income_statement (annual, 2025-12-31) — Net Income: -74896000.00
LAB income_statement (quarterly, 2025-12-31) — Net Income: 19283000.00
LAB income_statement (annual, 2025-12-31) — Net Income Common Stockholders: -74896000.00
LAB income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: 19283000.00
LAB income_statement (annual, 2025-12-31) — Net Income Continuous Operations: -58826000.00
LAB income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: 13901000.00
LAB income_statement (annual, 2025-12-31) — Net Income Discontinuous Operations: -16070000.00
LAB income_statement (quarterly, 2025-12-31) — Net Income Discontinuous Operations: 5382000.00
LAB income_statement (annual, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -74896000.00
LAB income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 19283000.00
LAB income_statement (annual, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -58826000.00
LAB income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 13901000.00
LAB cash_flow (annual, 2025-12-31) — Net Income From Continuing Operations: -74896000.00
LAB cash_flow (quarterly, 2025-12-31) — Net Income From Continuing Operations: 19283000.00
LAB income_statement (annual, 2025-12-31) — Net Income Including Noncontrolling Interests: -74896000.00
LAB income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: 19283000.00
LAB income_statement (annual, 2025-12-31) — Net Interest Income: 9153000.00
LAB income_statement (quarterly, 2025-12-31) — Net Interest Income: 1657000.00
LAB cash_flow (annual, 2025-12-31) — Net Investment Purchase And Sale: 40712000.00
LAB cash_flow (quarterly, 2025-12-31) — Net Investment Purchase And Sale: -2564000.00
LAB cash_flow (annual, 2025-12-31) — Net Issuance Payments Of Debt: 0.00
LAB cash_flow (quarterly, 2025-12-31) — Net Issuance Payments Of Debt: 0.00
LAB income_statement (annual, 2025-12-31) — Net Non Operating Interest Income Expense: 9153000.00
LAB income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: 1657000.00
LAB cash_flow (annual, 2025-12-31) — Net Other Financing Charges: -484000.00
LAB cash_flow (quarterly, 2025-12-31) — Net Other Financing Charges: -126000.00
LAB cash_flow (annual, 2025-12-31) — Net Other Investing Changes: -5000000.00
LAB balance_sheet (annual, 2025-12-31) — Net PPE: 46007000.00
LAB balance_sheet (quarterly, 2025-12-31) — Net PPE: 46007000.00
LAB cash_flow (annual, 2025-12-31) — Net PPE Purchase And Sale: -8303000.00
LAB cash_flow (quarterly, 2025-12-31) — Net PPE Purchase And Sale: -476000.00
LAB cash_flow (annual, 2025-12-31) — Net Short Term Debt Issuance: 0.00
LAB balance_sheet (annual, 2025-12-31) — Net Tangible Assets: 424291000.00
LAB balance_sheet (quarterly, 2025-12-31) — Net Tangible Assets: 424291000.00
LAB balance_sheet (annual, 2025-12-31) — Non Current Deferred Assets: 38628000.00
LAB balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Assets: 38628000.00
LAB balance_sheet (annual, 2025-12-31) — Non Current Deferred Liabilities: 8603000.00
LAB balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Liabilities: 8603000.00
LAB balance_sheet (annual, 2025-12-31) — Non Current Deferred Revenue: 7793000.00
LAB balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Revenue: 7793000.00
LAB balance_sheet (annual, 2025-12-31) — Non Current Deferred Taxes Assets: 38628000.00
LAB balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Taxes Assets: 38628000.00
LAB balance_sheet (annual, 2025-12-31) — Non Current Deferred Taxes Liabilities: 810000.00
LAB balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Taxes Liabilities: 810000.00
LAB income_statement (annual, 2025-12-31) — Normalized EBITDA: -68755000.00
LAB income_statement (quarterly, 2025-12-31) — Normalized EBITDA: -18015000.00
LAB income_statement (annual, 2025-12-31) — Normalized Income: -48524048.00
LAB income_statement (quarterly, 2025-12-31) — Normalized Income: 16049800.00
LAB cash_flow (annual, 2025-12-31) — Operating Cash Flow: -74343000.00
LAB cash_flow (quarterly, 2025-12-31) — Operating Cash Flow: -1190000.00
LAB cash_flow (annual, 2025-12-31) — Operating Gains Losses: -232000.00
LAB cash_flow (quarterly, 2025-12-31) — Operating Gains Losses: 0.00
LAB income_statement (annual, 2025-12-31) — Operating Income: -93305000.00
LAB income_statement (quarterly, 2025-12-31) — Operating Income: -21924000.00
LAB income_statement (annual, 2025-12-31) — Operating Revenue: 85331000.00
LAB income_statement (quarterly, 2025-12-31) — Operating Revenue: 23795000.00
LAB balance_sheet (annual, 2025-12-31) — Ordinary Shares Number: 386381000.00
LAB balance_sheet (quarterly, 2025-12-31) — Ordinary Shares Number: 386381000.00
LAB balance_sheet (annual, 2025-12-31) — Other Current Assets: 4871000.00
LAB balance_sheet (quarterly, 2025-12-31) — Other Current Assets: 4871000.00
LAB balance_sheet (annual, 2025-12-31) — Other Current Liabilities: 25633000.00
LAB balance_sheet (quarterly, 2025-12-31) — Other Current Liabilities: 25633000.00
LAB balance_sheet (annual, 2025-12-31) — Other Equity Adjustments: -1492000.00
LAB balance_sheet (quarterly, 2025-12-31) — Other Equity Adjustments: -1492000.00
LAB income_statement (annual, 2025-12-31) — Other Income Expense: -12550000.00
LAB income_statement (quarterly, 2025-12-31) — Other Income Expense: -1764000.00
LAB cash_flow (annual, 2025-12-31) — Other Non Cash Items: 3747000.00
LAB cash_flow (quarterly, 2025-12-31) — Other Non Cash Items: 3972000.00
LAB balance_sheet (annual, 2025-12-31) — Other Non Current Assets: 3154000.00
LAB balance_sheet (quarterly, 2025-12-31) — Other Non Current Assets: 3154000.00
LAB balance_sheet (annual, 2025-12-31) — Other Non Current Liabilities: 1215000.00
LAB balance_sheet (quarterly, 2025-12-31) — Other Non Current Liabilities: 1215000.00
LAB income_statement (annual, 2025-12-31) — Other Non Operating Income Expenses: 4394000.00
LAB income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: 956000.00
LAB balance_sheet (annual, 2025-12-31) — Other Properties: 62115000.00
LAB balance_sheet (quarterly, 2025-12-31) — Other Properties: 62115000.00
LAB balance_sheet (annual, 2025-12-31) — Other Short Term Investments: 66712000.00
LAB balance_sheet (quarterly, 2025-12-31) — Other Short Term Investments: 66712000.00
LAB balance_sheet (annual, 2025-12-31) — Payables: 5407000.00
LAB balance_sheet (quarterly, 2025-12-31) — Payables: 5407000.00
LAB balance_sheet (annual, 2025-12-31) — Payables And Accrued Expenses: 16103000.00
LAB balance_sheet (quarterly, 2025-12-31) — Payables And Accrued Expenses: 16103000.00
LAB balance_sheet (annual, 2025-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 18146000.00
LAB balance_sheet (quarterly, 2025-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 18146000.00
LAB balance_sheet (annual, 2025-12-31) — Preferred Stock: 0.00
LAB balance_sheet (quarterly, 2025-12-31) — Preferred Stock: 0.00
LAB income_statement (annual, 2025-12-31) — Pretax Income: -96702000.00
LAB income_statement (quarterly, 2025-12-31) — Pretax Income: -22031000.00
LAB cash_flow (annual, 2025-12-31) — Proceeds From Stock Option Exercised: 1054000.00
LAB cash_flow (quarterly, 2025-12-31) — Proceeds From Stock Option Exercised: 746000.00
LAB balance_sheet (annual, 2025-12-31) — Properties: 0.00
LAB balance_sheet (quarterly, 2025-12-31) — Properties: 0.00
LAB cash_flow (annual, 2025-12-31) — Provisionand Write Offof Assets: 3468000.00
LAB cash_flow (quarterly, 2025-12-31) — Provisionand Write Offof Assets: 1493000.00
LAB cash_flow (annual, 2025-12-31) — Purchase Of Business: 0.00
LAB cash_flow (annual, 2025-12-31) — Purchase Of Investment: -138288000.00
LAB cash_flow (quarterly, 2025-12-31) — Purchase Of Investment: -27564000.00
LAB cash_flow (annual, 2025-12-31) — Purchase Of PPE: -8303000.00
LAB cash_flow (quarterly, 2025-12-31) — Purchase Of PPE: -476000.00
LAB balance_sheet (annual, 2025-12-31) — Raw Materials: 8631000.00
LAB balance_sheet (quarterly, 2025-12-31) — Raw Materials: 8631000.00
LAB balance_sheet (annual, 2025-12-31) — Receivables: 13431000.00
LAB balance_sheet (quarterly, 2025-12-31) — Receivables: 13431000.00
LAB income_statement (annual, 2025-12-31) — Reconciled Cost Of Revenue: 42788000.00
LAB income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 12413000.00
LAB income_statement (annual, 2025-12-31) — Reconciled Depreciation: 10977000.00
LAB income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 1291000.00
LAB cash_flow (annual, 2025-12-31) — Repayment Of Debt: 0.00
LAB cash_flow (quarterly, 2025-12-31) — Repayment Of Debt: 0.00
LAB cash_flow (annual, 2025-12-31) — Repurchase Of Capital Stock: 0.00
LAB cash_flow (quarterly, 2025-12-31) — Repurchase Of Capital Stock: 0.00
LAB income_statement (annual, 2025-12-31) — Research And Development: 25987000.00
LAB income_statement (quarterly, 2025-12-31) — Research And Development: 7969000.00
LAB income_statement (annual, 2025-12-31) — Restructuring And Mergern Acquisition: 16944000.00
LAB income_statement (quarterly, 2025-12-31) — Restructuring And Mergern Acquisition: 2720000.00
LAB balance_sheet (annual, 2025-12-31) — Retained Earnings: -1260547000.00
LAB balance_sheet (quarterly, 2025-12-31) — Retained Earnings: -1260547000.00
LAB cash_flow (annual, 2025-12-31) — Sale Of Business: 0.00
LAB cash_flow (annual, 2025-12-31) — Sale Of Investment: 179000000.00
LAB cash_flow (quarterly, 2025-12-31) — Sale Of Investment: 25000000.00
LAB income_statement (annual, 2025-12-31) — Selling General And Administration: 109861000.00
LAB income_statement (quarterly, 2025-12-31) — Selling General And Administration: 25337000.00
LAB balance_sheet (annual, 2025-12-31) — Share Issued: 404961000.00
LAB balance_sheet (quarterly, 2025-12-31) — Share Issued: 404961000.00
LAB cash_flow (annual, 2025-12-31) — Short Term Debt Payments: 0.00
LAB income_statement (annual, 2025-12-31) — Special Income Charges: -16944000.00
LAB income_statement (quarterly, 2025-12-31) — Special Income Charges: -2720000.00
LAB cash_flow (annual, 2025-12-31) — Stock Based Compensation: 29613000.00
LAB cash_flow (quarterly, 2025-12-31) — Stock Based Compensation: 5743000.00
LAB balance_sheet (annual, 2025-12-31) — Stockholders Equity: 424291000.00
LAB balance_sheet (quarterly, 2025-12-31) — Stockholders Equity: 424291000.00
LAB balance_sheet (annual, 2025-12-31) — Tangible Book Value: 424291000.00
LAB balance_sheet (quarterly, 2025-12-31) — Tangible Book Value: 424291000.00
LAB income_statement (annual, 2025-12-31) — Tax Effect Of Unusual Items: -6642048.00
LAB income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: -571200.00
LAB income_statement (annual, 2025-12-31) — Tax Provision: -37876000.00
LAB income_statement (quarterly, 2025-12-31) — Tax Provision: -35932000.00
LAB income_statement (annual, 2025-12-31) — Tax Rate For Calcs: 0.39
LAB income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.21
LAB balance_sheet (annual, 2025-12-31) — Total Assets: 567754000.00
LAB balance_sheet (quarterly, 2025-12-31) — Total Assets: 567754000.00
LAB balance_sheet (annual, 2025-12-31) — Total Capitalization: 424590000.00
LAB balance_sheet (quarterly, 2025-12-31) — Total Capitalization: 424590000.00
LAB balance_sheet (annual, 2025-12-31) — Total Debt: 30827000.00
LAB balance_sheet (quarterly, 2025-12-31) — Total Debt: 30827000.00
LAB balance_sheet (annual, 2025-12-31) — Total Equity Gross Minority Interest: 424291000.00
LAB balance_sheet (quarterly, 2025-12-31) — Total Equity Gross Minority Interest: 424291000.00
LAB income_statement (annual, 2025-12-31) — Total Expenses: 178636000.00
LAB income_statement (quarterly, 2025-12-31) — Total Expenses: 45719000.00
LAB balance_sheet (annual, 2025-12-31) — Total Liabilities Net Minority Interest: 143463000.00
LAB balance_sheet (quarterly, 2025-12-31) — Total Liabilities Net Minority Interest: 143463000.00
LAB balance_sheet (annual, 2025-12-31) — Total Non Current Assets: 113490000.00
LAB balance_sheet (quarterly, 2025-12-31) — Total Non Current Assets: 113490000.00
LAB balance_sheet (annual, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 35155000.00
LAB balance_sheet (quarterly, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 35155000.00
LAB income_statement (annual, 2025-12-31) — Total Operating Income As Reported: -110249000.00
LAB income_statement (quarterly, 2025-12-31) — Total Operating Income As Reported: -24644000.00
LAB income_statement (annual, 2025-12-31) — Total Unusual Items: -16944000.00
LAB income_statement (quarterly, 2025-12-31) — Total Unusual Items: -2720000.00
LAB income_statement (annual, 2025-12-31) — Total Unusual Items Excluding Goodwill: -16944000.00
LAB income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: -2720000.00
LAB balance_sheet (annual, 2025-12-31) — Treasury Shares Number: 18580000.00
LAB balance_sheet (quarterly, 2025-12-31) — Treasury Shares Number: 18580000.00
LAB balance_sheet (annual, 2025-12-31) — Treasury Stock: 46467000.00
LAB balance_sheet (quarterly, 2025-12-31) — Treasury Stock: 46467000.00
LAB cash_flow (annual, 2025-12-31) — Unrealized Gain Loss On Investment Securities: 602000.00
LAB balance_sheet (annual, 2025-12-31) — Work In Process: 253000.00
LAB balance_sheet (quarterly, 2025-12-31) — Work In Process: 253000.00
LAB balance_sheet (annual, 2025-12-31) — Working Capital: 345956000.00
LAB balance_sheet (quarterly, 2025-12-31) — Working Capital: 345956000.00
LAB income_statement (quarterly, 2026-03-31) — +Operating Expense: 20724000.00
LAB income_statement (quarterly, 2026-03-31) — +Total Revenue: 21146000.00
LAB balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 8007000.00
LAB balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 16637000.00
LAB balance_sheet (quarterly, 2026-03-31) — Accumulated Depreciation: -49030000.00
LAB balance_sheet (quarterly, 2026-03-31) — Additional Paid In Capital: 1741172000.00
LAB balance_sheet (quarterly, 2026-03-31) — Allowance For Doubtful Accounts Receivable: -250000.00
LAB cash_flow (quarterly, 2026-03-31) — Amortization Cash Flow: 0.00
LAB cash_flow (quarterly, 2026-03-31) — Amortization Of Intangibles: 0.00
LAB cash_flow (quarterly, 2026-03-31) — Amortization Of Securities: -632000.00
LAB balance_sheet (quarterly, 2026-03-31) — Assets Held For Sale Current: 0.00
LAB income_statement (quarterly, 2026-03-31) — Basic Average Shares: 388202000.00
LAB income_statement (quarterly, 2026-03-31) — Basic EPS: 0.33
LAB cash_flow (quarterly, 2026-03-31) — Beginning Cash Position: 123296000.00
LAB cash_flow (quarterly, 2026-03-31) — Capital Expenditure: -570000.00
LAB balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 29192000.00
LAB balance_sheet (quarterly, 2026-03-31) — Capital Stock: 408000.00
LAB balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 265772000.00
LAB balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 455176000.00
LAB cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Financing Activities: -40000.00
LAB cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Investing Activities: 191090000.00
LAB cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Operating Activities: -46597000.00
LAB cash_flow (quarterly, 2026-03-31) — Change In Account Payable: -1224000.00
LAB cash_flow (quarterly, 2026-03-31) — Change In Accrued Expense: -20785000.00
LAB cash_flow (quarterly, 2026-03-31) — Change In Inventory: 1935000.00
LAB cash_flow (quarterly, 2026-03-31) — Change In Other Current Liabilities: -1489000.00
LAB cash_flow (quarterly, 2026-03-31) — Change In Other Working Capital: -29934000.00
LAB cash_flow (quarterly, 2026-03-31) — Change In Payable: -1224000.00
LAB cash_flow (quarterly, 2026-03-31) — Change In Payables And Accrued Expense: -22009000.00
LAB cash_flow (quarterly, 2026-03-31) — Change In Prepaid Assets: -1592000.00
LAB cash_flow (quarterly, 2026-03-31) — Change In Receivables: 36501000.00
LAB cash_flow (quarterly, 2026-03-31) — Change In Working Capital: -16588000.00
LAB cash_flow (quarterly, 2026-03-31) — Changes In Account Receivables: -1858000.00
LAB cash_flow (quarterly, 2026-03-31) — Changes In Cash: 144453000.00
LAB balance_sheet (quarterly, 2026-03-31) — Common Stock: 408000.00
LAB balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 561123000.00
LAB balance_sheet (quarterly, 2026-03-31) — Construction In Progress: 823000.00
LAB income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 9838000.00
LAB balance_sheet (quarterly, 2026-03-31) — Current Accrued Expenses: 6837000.00
LAB balance_sheet (quarterly, 2026-03-31) — Current Assets: 521453000.00
LAB balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 5540000.00
LAB balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 5540000.00
LAB balance_sheet (quarterly, 2026-03-31) — Current Deferred Liabilities: 13842000.00
LAB balance_sheet (quarterly, 2026-03-31) — Current Deferred Revenue: 13842000.00
LAB balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 42203000.00
LAB cash_flow (quarterly, 2026-03-31) — Depreciation: 1408000.00
LAB cash_flow (quarterly, 2026-03-31) — Depreciation Amortization Depletion: 1408000.00
LAB cash_flow (quarterly, 2026-03-31) — Depreciation And Amortization: 1408000.00
LAB income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 388202000.00
LAB income_statement (quarterly, 2026-03-31) — Diluted EPS: 0.33
LAB income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: 127068000.00
LAB income_statement (quarterly, 2026-03-31) — EBIT: -9416000.00
LAB income_statement (quarterly, 2026-03-31) — EBITDA: -8008000.00
LAB cash_flow (quarterly, 2026-03-31) — Effect Of Exchange Rate Changes: 115000.00
LAB cash_flow (quarterly, 2026-03-31) — End Cash Position: 267864000.00
LAB cash_flow (quarterly, 2026-03-31) — Financing Cash Flow: -40000.00
LAB balance_sheet (quarterly, 2026-03-31) — Finished Goods: 8701000.00
LAB cash_flow (quarterly, 2026-03-31) — Free Cash Flow: -47167000.00
LAB cash_flow (quarterly, 2026-03-31) — Gain Loss On Sale Of Business: -172289000.00
LAB balance_sheet (quarterly, 2026-03-31) — Gains Losses Not Affecting Retained Earnings: -511000.00
LAB balance_sheet (quarterly, 2026-03-31) — Gross Accounts Receivable: 16887000.00
LAB balance_sheet (quarterly, 2026-03-31) — Gross PPE: 91678000.00
LAB income_statement (quarterly, 2026-03-31) — Gross Profit: 11308000.00
LAB cash_flow (quarterly, 2026-03-31) — Income Tax Paid Supplemental Data: 9000.00
LAB income_statement (quarterly, 2026-03-31) — Interest Income: 3511000.00
LAB income_statement (quarterly, 2026-03-31) — Interest Income Non Operating: 3511000.00
LAB cash_flow (quarterly, 2026-03-31) — Interest Paid Supplemental Data: 4000.00
LAB balance_sheet (quarterly, 2026-03-31) — Inventory: 18594000.00
LAB balance_sheet (quarterly, 2026-03-31) — Invested Capital: 561422000.00
LAB cash_flow (quarterly, 2026-03-31) — Investing Cash Flow: 191090000.00
LAB balance_sheet (quarterly, 2026-03-31) — Investments And Advances: 71357000.00
LAB balance_sheet (quarterly, 2026-03-31) — Leases: 13936000.00
LAB balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 23652000.00
LAB balance_sheet (quarterly, 2026-03-31) — Long Term Debt: 299000.00
LAB balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 23951000.00
LAB balance_sheet (quarterly, 2026-03-31) — Machinery Furniture Equipment: 17029000.00
LAB cash_flow (quarterly, 2026-03-31) — Net Business Purchase And Sale: 363222000.00
LAB income_statement (quarterly, 2026-03-31) — Net Income: 127068000.00
LAB income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: 127068000.00
LAB income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: -14626000.00
LAB income_statement (quarterly, 2026-03-31) — Net Income Discontinuous Operations: 141694000.00
LAB income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 127068000.00
LAB income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: -14626000.00
LAB cash_flow (quarterly, 2026-03-31) — Net Income From Continuing Operations: 127068000.00
LAB income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: 127068000.00
LAB income_statement (quarterly, 2026-03-31) — Net Interest Income: 3511000.00
LAB cash_flow (quarterly, 2026-03-31) — Net Investment Purchase And Sale: -171562000.00
LAB income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: 3511000.00
LAB cash_flow (quarterly, 2026-03-31) — Net Other Financing Charges: -118000.00
LAB balance_sheet (quarterly, 2026-03-31) — Net PPE: 42648000.00
LAB cash_flow (quarterly, 2026-03-31) — Net PPE Purchase And Sale: -570000.00
LAB balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 561123000.00
LAB balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Assets: 270000.00
LAB balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Liabilities: 7393000.00
LAB balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Revenue: 6570000.00
LAB balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Assets: 270000.00
LAB balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Liabilities: 823000.00
LAB income_statement (quarterly, 2026-03-31) — Normalized EBITDA: -4928000.00
LAB income_statement (quarterly, 2026-03-31) — Normalized Income: -12778000.00
LAB cash_flow (quarterly, 2026-03-31) — Operating Cash Flow: -46597000.00
LAB cash_flow (quarterly, 2026-03-31) — Operating Gains Losses: -172289000.00
LAB income_statement (quarterly, 2026-03-31) — Operating Income: -9416000.00
LAB income_statement (quarterly, 2026-03-31) — Operating Revenue: 21146000.00
LAB balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 390141000.00
LAB balance_sheet (quarterly, 2026-03-31) — Other Current Assets: 6046000.00
LAB balance_sheet (quarterly, 2026-03-31) — Other Equity Adjustments: -511000.00
LAB income_statement (quarterly, 2026-03-31) — Other Income Expense: -8710000.00
LAB cash_flow (quarterly, 2026-03-31) — Other Non Cash Items: 1422000.00
LAB balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: 3386000.00
LAB balance_sheet (quarterly, 2026-03-31) — Other Non Current Liabilities: 4444000.00
LAB income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: -5630000.00
LAB balance_sheet (quarterly, 2026-03-31) — Other Properties: 59890000.00
LAB balance_sheet (quarterly, 2026-03-31) — Other Receivables: 25000000.00
LAB balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 189404000.00
LAB balance_sheet (quarterly, 2026-03-31) — Payables: 10990000.00
LAB balance_sheet (quarterly, 2026-03-31) — Payables And Accrued Expenses: 17827000.00
LAB balance_sheet (quarterly, 2026-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 4994000.00
LAB balance_sheet (quarterly, 2026-03-31) — Preferred Stock: 0.00
LAB income_statement (quarterly, 2026-03-31) — Pretax Income: -14615000.00
LAB cash_flow (quarterly, 2026-03-31) — Proceeds From Stock Option Exercised: 78000.00
LAB balance_sheet (quarterly, 2026-03-31) — Properties: 0.00
LAB cash_flow (quarterly, 2026-03-31) — Provisionand Write Offof Assets: 696000.00
LAB cash_flow (quarterly, 2026-03-31) — Purchase Of Investment: -186562000.00
LAB cash_flow (quarterly, 2026-03-31) — Purchase Of PPE: -570000.00
LAB balance_sheet (quarterly, 2026-03-31) — Raw Materials: 9395000.00
LAB balance_sheet (quarterly, 2026-03-31) — Receivables: 41637000.00
LAB income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 9838000.00
LAB income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 1408000.00
LAB income_statement (quarterly, 2026-03-31) — Research And Development: 2117000.00
LAB income_statement (quarterly, 2026-03-31) — Restructuring And Mergern Acquisition: 3080000.00
LAB balance_sheet (quarterly, 2026-03-31) — Retained Earnings: -1133479000.00
LAB cash_flow (quarterly, 2026-03-31) — Sale Of Business: 363222000.00
LAB cash_flow (quarterly, 2026-03-31) — Sale Of Investment: 15000000.00
LAB income_statement (quarterly, 2026-03-31) — Selling General And Administration: 18607000.00
LAB balance_sheet (quarterly, 2026-03-31) — Share Issued: 408721000.00
LAB income_statement (quarterly, 2026-03-31) — Special Income Charges: -3080000.00
LAB cash_flow (quarterly, 2026-03-31) — Stock Based Compensation: 8824000.00
LAB balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 561123000.00
LAB balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 561123000.00
LAB income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: -1232000.00
LAB income_statement (quarterly, 2026-03-31) — Tax Provision: 11000.00
LAB income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.40
LAB balance_sheet (quarterly, 2026-03-31) — Total Assets: 639114000.00
LAB balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 561422000.00
LAB balance_sheet (quarterly, 2026-03-31) — Total Debt: 29491000.00
LAB balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 561123000.00
LAB income_statement (quarterly, 2026-03-31) — Total Expenses: 30562000.00
LAB balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 77991000.00
LAB balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 117661000.00
LAB balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 35788000.00
LAB income_statement (quarterly, 2026-03-31) — Total Operating Income As Reported: -12496000.00
LAB balance_sheet (quarterly, 2026-03-31) — Total Tax Payable: 2983000.00
LAB income_statement (quarterly, 2026-03-31) — Total Unusual Items: -3080000.00
LAB income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: -3080000.00
LAB balance_sheet (quarterly, 2026-03-31) — Treasury Shares Number: 18580000.00
LAB balance_sheet (quarterly, 2026-03-31) — Treasury Stock: 46467000.00
LAB cash_flow (quarterly, 2026-03-31) — Unrealized Gain Loss On Investment Securities: 3494000.00
LAB balance_sheet (quarterly, 2026-03-31) — Work In Process: 498000.00
LAB balance_sheet (quarterly, 2026-03-31) — Working Capital: 479250000.00
LAB.V income_statement (annual, 2021-09-30) — Amortization: 1432.00
LAB.V income_statement (annual, 2021-09-30) — Amortization Of Intangibles Income Statement: 1432.00
LAB.V balance_sheet (annual, 2021-09-30) — Cash Financial: 33245743.00
LAB.V cash_flow (annual, 2021-09-30) — Cash Flow From Continuing Financing Activities: 34511046.00
LAB.V cash_flow (annual, 2021-09-30) — Common Stock Issuance: 28850000.00
LAB.V balance_sheet (annual, 2021-09-30) — Current Deferred Liabilities: 1144254.00
LAB.V income_statement (annual, 2021-09-30) — Depreciation Amortization Depletion Income Statement: 1432.00
LAB.V income_statement (annual, 2021-09-30) — Depreciation And Amortization In Income Statement: 1432.00
LAB.V cash_flow (annual, 2021-09-30) — Financing Cash Flow: 34511046.00
LAB.V balance_sheet (annual, 2021-09-30) — Gross PPE: 12623659.00
LAB.V cash_flow (annual, 2021-09-30) — Issuance Of Capital Stock: 28850000.00
LAB.V balance_sheet (annual, 2021-09-30) — Machinery Furniture Equipment: 6221.00
LAB.V cash_flow (annual, 2021-09-30) — Net Common Stock Issuance: 28850000.00
LAB.V cash_flow (annual, 2021-09-30) — Net Other Financing Charges: -283534.00
LAB.V cash_flow (annual, 2021-09-30) — Net Other Investing Changes: -6224549.00
LAB.V balance_sheet (annual, 2021-09-30) — Non Current Deferred Liabilities: 0.00
LAB.V balance_sheet (annual, 2021-09-30) — Non Current Deferred Taxes Liabilities: 0.00
LAB.V cash_flow (annual, 2021-09-30) — Other Non Cash Items: -1575687.00
LAB.V balance_sheet (annual, 2021-09-30) — Other Properties: 12623659.00
LAB.V cash_flow (annual, 2021-09-30) — Proceeds From Stock Option Exercised: 5944580.00
LAB.V income_statement (annual, 2022-09-30) — +Operating Expense: 1246453.00
LAB.V income_statement (annual, 2022-09-30) — +Total Revenue: 0.00
LAB.V balance_sheet (annual, 2022-09-30) — Accounts Receivable: 559637.00
LAB.V cash_flow (annual, 2022-09-30) — Amortization Cash Flow: 11995.00
LAB.V cash_flow (annual, 2022-09-30) — Amortization Of Intangibles: 11995.00
LAB.V cash_flow (annual, 2022-09-30) — Asset Impairment Charge: 105000.00
LAB.V income_statement (annual, 2022-09-30) — Basic Average Shares: 159050274.00
LAB.V income_statement (annual, 2022-09-30) — Basic EPS: -0.01
LAB.V cash_flow (annual, 2022-09-30) — Beginning Cash Position: 33245743.00
LAB.V cash_flow (annual, 2022-09-30) — Capital Expenditure: -14695387.00
LAB.V balance_sheet (annual, 2022-09-30) — Capital Stock: 61149278.00
LAB.V balance_sheet (annual, 2022-09-30) — Cash And Cash Equivalents: 21354986.00
LAB.V balance_sheet (annual, 2022-09-30) — Cash Cash Equivalents And Short Term Investments: 21354986.00
LAB.V balance_sheet (annual, 2022-09-30) — Cash Financial: 21354986.00
LAB.V cash_flow (annual, 2022-09-30) — Cash Flow From Continuing Financing Activities: 4244057.00
LAB.V cash_flow (annual, 2022-09-30) — Cash Flow From Continuing Investing Activities: -14695387.00
LAB.V cash_flow (annual, 2022-09-30) — Cash Flow From Continuing Operating Activities: -1439427.00
LAB.V cash_flow (annual, 2022-09-30) — Change In Payables And Accrued Expense: -91248.00
LAB.V cash_flow (annual, 2022-09-30) — Change In Prepaid Assets: -16124.00
LAB.V cash_flow (annual, 2022-09-30) — Change In Receivables: -103558.00
LAB.V cash_flow (annual, 2022-09-30) — Change In Working Capital: -210930.00
LAB.V cash_flow (annual, 2022-09-30) — Changes In Cash: -11890757.00
LAB.V balance_sheet (annual, 2022-09-30) — Common Stock: 61149278.00
LAB.V balance_sheet (annual, 2022-09-30) — Common Stock Equity: 48933348.00
LAB.V cash_flow (annual, 2022-09-30) — Common Stock Issuance: 0.00
LAB.V income_statement (annual, 2022-09-30) — Cost Of Revenue: 11995.00
LAB.V balance_sheet (annual, 2022-09-30) — Current Assets: 22000441.00
LAB.V balance_sheet (annual, 2022-09-30) — Current Deferred Liabilities: 0.00
LAB.V balance_sheet (annual, 2022-09-30) — Current Liabilities: 926799.00
LAB.V cash_flow (annual, 2022-09-30) — Deferred Income Tax: 983566.00
LAB.V cash_flow (annual, 2022-09-30) — Deferred Tax: 983566.00
LAB.V cash_flow (annual, 2022-09-30) — Depreciation Amortization Depletion: 11995.00
LAB.V cash_flow (annual, 2022-09-30) — Depreciation And Amortization: 11995.00
LAB.V income_statement (annual, 2022-09-30) — Diluted Average Shares: 159050274.00
LAB.V income_statement (annual, 2022-09-30) — Diluted EPS: -0.01
LAB.V income_statement (annual, 2022-09-30) — Diluted NI Availto Com Stockholders: -1184804.00
LAB.V income_statement (annual, 2022-09-30) — EBIT: -1258448.00
LAB.V income_statement (annual, 2022-09-30) — EBITDA: -1246453.00
LAB.V cash_flow (annual, 2022-09-30) — End Cash Position: 21354986.00
LAB.V cash_flow (annual, 2022-09-30) — Financing Cash Flow: 4244057.00
LAB.V cash_flow (annual, 2022-09-30) — Free Cash Flow: -16134814.00
LAB.V income_statement (annual, 2022-09-30) — General And Administrative Expense: 380447.00
LAB.V balance_sheet (annual, 2022-09-30) — Gross PPE: 28843272.00
LAB.V income_statement (annual, 2022-09-30) — Gross Profit: -11995.00
LAB.V income_statement (annual, 2022-09-30) — Impairment Of Capital Assets: 105000.00
LAB.V balance_sheet (annual, 2022-09-30) — Invested Capital: 48933348.00
LAB.V cash_flow (annual, 2022-09-30) — Investing Cash Flow: -14695387.00
LAB.V cash_flow (annual, 2022-09-30) — Issuance Of Capital Stock: 0.00
LAB.V cash_flow (annual, 2022-09-30) — Net Common Stock Issuance: 0.00
LAB.V income_statement (annual, 2022-09-30) — Net Income: -1184804.00
LAB.V income_statement (annual, 2022-09-30) — Net Income Common Stockholders: -1184804.00
LAB.V income_statement (annual, 2022-09-30) — Net Income Continuous Operations: -1184804.00
LAB.V income_statement (annual, 2022-09-30) — Net Income From Continuing And Discontinued Operation: -1184804.00
LAB.V income_statement (annual, 2022-09-30) — Net Income From Continuing Operation Net Minority Interest: -1184804.00
LAB.V cash_flow (annual, 2022-09-30) — Net Income From Continuing Operations: -1184804.00
LAB.V income_statement (annual, 2022-09-30) — Net Income Including Noncontrolling Interests: -1184804.00
LAB.V cash_flow (annual, 2022-09-30) — Net Other Investing Changes: -12364665.00
LAB.V balance_sheet (annual, 2022-09-30) — Net PPE: 28843272.00
LAB.V cash_flow (annual, 2022-09-30) — Net PPE Purchase And Sale: -14695387.00
LAB.V balance_sheet (annual, 2022-09-30) — Net Tangible Assets: 48933348.00
LAB.V balance_sheet (annual, 2022-09-30) — Non Current Deferred Liabilities: 983566.00
LAB.V balance_sheet (annual, 2022-09-30) — Non Current Deferred Taxes Liabilities: 983566.00
LAB.V income_statement (annual, 2022-09-30) — Normalized EBITDA: -1141453.00
LAB.V income_statement (annual, 2022-09-30) — Normalized Income: -1107324.50
LAB.V cash_flow (annual, 2022-09-30) — Operating Cash Flow: -1439427.00
LAB.V income_statement (annual, 2022-09-30) — Operating Income: -1258448.00
LAB.V income_statement (annual, 2022-09-30) — Operating Revenue: 0.00
LAB.V balance_sheet (annual, 2022-09-30) — Ordinary Shares Number: 169189979.00
LAB.V balance_sheet (annual, 2022-09-30) — Other Equity Interest: 4419099.00
LAB.V income_statement (annual, 2022-09-30) — Other Gand A: 380447.00
LAB.V income_statement (annual, 2022-09-30) — Other Income Expense: 1057210.00
LAB.V cash_flow (annual, 2022-09-30) — Other Non Cash Items: -1144254.00
LAB.V income_statement (annual, 2022-09-30) — Other Non Operating Income Expenses: 1162210.00
LAB.V income_statement (annual, 2022-09-30) — Other Operating Expenses: 866006.00
LAB.V balance_sheet (annual, 2022-09-30) — Other Properties: 28843272.00
LAB.V balance_sheet (annual, 2022-09-30) — Payables And Accrued Expenses: 926799.00
LAB.V balance_sheet (annual, 2022-09-30) — Prepaid Assets: 85818.00
LAB.V income_statement (annual, 2022-09-30) — Pretax Income: -201238.00
LAB.V cash_flow (annual, 2022-09-30) — Proceeds From Stock Option Exercised: 4244057.00
LAB.V cash_flow (annual, 2022-09-30) — Purchase Of PPE: -14695387.00
LAB.V balance_sheet (annual, 2022-09-30) — Receivables: 559637.00
LAB.V income_statement (annual, 2022-09-30) — Reconciled Cost Of Revenue: 11995.00
LAB.V income_statement (annual, 2022-09-30) — Reconciled Depreciation: 11995.00
LAB.V balance_sheet (annual, 2022-09-30) — Retained Earnings: -16635029.00
LAB.V income_statement (annual, 2022-09-30) — Salaries And Wages: 0.00
LAB.V income_statement (annual, 2022-09-30) — Selling General And Administration: 380447.00
LAB.V balance_sheet (annual, 2022-09-30) — Share Issued: 169189979.00
LAB.V income_statement (annual, 2022-09-30) — Special Income Charges: -105000.00
LAB.V cash_flow (annual, 2022-09-30) — Stock Based Compensation: 0.00
LAB.V balance_sheet (annual, 2022-09-30) — Stockholders Equity: 48933348.00
LAB.V balance_sheet (annual, 2022-09-30) — Tangible Book Value: 48933348.00
LAB.V income_statement (annual, 2022-09-30) — Tax Effect Of Unusual Items: -27520.50
LAB.V income_statement (annual, 2022-09-30) — Tax Provision: 983566.00
LAB.V income_statement (annual, 2022-09-30) — Tax Rate For Calcs: 0.26
LAB.V balance_sheet (annual, 2022-09-30) — Total Assets: 50843713.00
LAB.V balance_sheet (annual, 2022-09-30) — Total Capitalization: 48933348.00
LAB.V balance_sheet (annual, 2022-09-30) — Total Equity Gross Minority Interest: 48933348.00
LAB.V income_statement (annual, 2022-09-30) — Total Expenses: 1258448.00
LAB.V balance_sheet (annual, 2022-09-30) — Total Liabilities Net Minority Interest: 1910365.00
LAB.V balance_sheet (annual, 2022-09-30) — Total Non Current Assets: 28843272.00
LAB.V balance_sheet (annual, 2022-09-30) — Total Non Current Liabilities Net Minority Interest: 983566.00
LAB.V income_statement (annual, 2022-09-30) — Total Unusual Items: -105000.00
LAB.V income_statement (annual, 2022-09-30) — Total Unusual Items Excluding Goodwill: -105000.00
LAB.V balance_sheet (annual, 2022-09-30) — Working Capital: 21073642.00
LAB.V income_statement (annual, 2023-09-30) — +Operating Expense: 1275200.00
LAB.V income_statement (annual, 2023-09-30) — +Total Revenue: 0.00
LAB.V balance_sheet (annual, 2023-09-30) — Accounts Receivable: 482315.00
LAB.V cash_flow (annual, 2023-09-30) — Amortization Cash Flow: 17920.00
LAB.V cash_flow (annual, 2023-09-30) — Amortization Of Intangibles: 17920.00
LAB.V cash_flow (annual, 2023-09-30) — Asset Impairment Charge: 16000.00
LAB.V income_statement (annual, 2023-09-30) — Basic Average Shares: 169846527.00
LAB.V income_statement (annual, 2023-09-30) — Basic EPS: 0.00
LAB.V cash_flow (annual, 2023-09-30) — Beginning Cash Position: 21354986.00
LAB.V cash_flow (annual, 2023-09-30) — Capital Expenditure: -10961202.00
LAB.V balance_sheet (annual, 2023-09-30) — Capital Stock: 61472277.00
LAB.V balance_sheet (annual, 2023-09-30) — Cash And Cash Equivalents: 10081678.00
LAB.V balance_sheet (annual, 2023-09-30) — Cash Cash Equivalents And Short Term Investments: 10081678.00
LAB.V cash_flow (annual, 2023-09-30) — Cash Flow From Continuing Financing Activities: 164000.00
LAB.V cash_flow (annual, 2023-09-30) — Cash Flow From Continuing Investing Activities: -10961202.00
LAB.V cash_flow (annual, 2023-09-30) — Cash Flow From Continuing Operating Activities: -476106.00
LAB.V cash_flow (annual, 2023-09-30) — Change In Payables And Accrued Expense: 30353.00
LAB.V cash_flow (annual, 2023-09-30) — Change In Prepaid Assets: 7987.00
LAB.V cash_flow (annual, 2023-09-30) — Change In Receivables: 77322.00
LAB.V cash_flow (annual, 2023-09-30) — Change In Working Capital: 115662.00
LAB.V cash_flow (annual, 2023-09-30) — Changes In Cash: -11273308.00
LAB.V balance_sheet (annual, 2023-09-30) — Common Stock: 61472277.00
LAB.V balance_sheet (annual, 2023-09-30) — Common Stock Equity: 48637417.00
LAB.V income_statement (annual, 2023-09-30) — Cost Of Revenue: 17920.00
LAB.V balance_sheet (annual, 2023-09-30) — Current Assets: 10641824.00
LAB.V balance_sheet (annual, 2023-09-30) — Current Liabilities: 999317.00
LAB.V cash_flow (annual, 2023-09-30) — Deferred Income Tax: -165757.00
LAB.V cash_flow (annual, 2023-09-30) — Deferred Tax: -165757.00
LAB.V cash_flow (annual, 2023-09-30) — Depreciation Amortization Depletion: 17920.00
LAB.V cash_flow (annual, 2023-09-30) — Depreciation And Amortization: 17920.00
LAB.V income_statement (annual, 2023-09-30) — Diluted Average Shares: 169846527.00
LAB.V income_statement (annual, 2023-09-30) — Diluted EPS: 0.00
LAB.V income_statement (annual, 2023-09-30) — Diluted NI Availto Com Stockholders: -796854.00
LAB.V income_statement (annual, 2023-09-30) — EBIT: -1293120.00
LAB.V income_statement (annual, 2023-09-30) — EBITDA: -1275200.00
LAB.V cash_flow (annual, 2023-09-30) — End Cash Position: 10081678.00
LAB.V cash_flow (annual, 2023-09-30) — Financing Cash Flow: 164000.00
LAB.V cash_flow (annual, 2023-09-30) — Free Cash Flow: -11437308.00
LAB.V cash_flow (annual, 2023-09-30) — Gain Loss On Sale Of PPE: 0.00
LAB.V income_statement (annual, 2023-09-30) — Gain On Sale Of Ppe: 0.00
LAB.V income_statement (annual, 2023-09-30) — General And Administrative Expense: 723976.00
LAB.V balance_sheet (annual, 2023-09-30) — Gross PPE: 39812719.00
LAB.V income_statement (annual, 2023-09-30) — Gross Profit: -17920.00
LAB.V income_statement (annual, 2023-09-30) — Impairment Of Capital Assets: 16000.00
LAB.V balance_sheet (annual, 2023-09-30) — Invested Capital: 48637417.00
LAB.V cash_flow (annual, 2023-09-30) — Investing Cash Flow: -10961202.00
LAB.V income_statement (annual, 2023-09-30) — Net Income: -796854.00
LAB.V income_statement (annual, 2023-09-30) — Net Income Common Stockholders: -796854.00
LAB.V income_statement (annual, 2023-09-30) — Net Income Continuous Operations: -796854.00
LAB.V income_statement (annual, 2023-09-30) — Net Income From Continuing And Discontinued Operation: -796854.00
LAB.V income_statement (annual, 2023-09-30) — Net Income From Continuing Operation Net Minority Interest: -796854.00
LAB.V cash_flow (annual, 2023-09-30) — Net Income From Continuing Operations: -796854.00
LAB.V income_statement (annual, 2023-09-30) — Net Income Including Noncontrolling Interests: -796854.00
LAB.V balance_sheet (annual, 2023-09-30) — Net PPE: 39812719.00
LAB.V cash_flow (annual, 2023-09-30) — Net PPE Purchase And Sale: -10961202.00
LAB.V balance_sheet (annual, 2023-09-30) — Net Tangible Assets: 48637417.00
LAB.V balance_sheet (annual, 2023-09-30) — Non Current Deferred Liabilities: 817809.00
LAB.V balance_sheet (annual, 2023-09-30) — Non Current Deferred Taxes Liabilities: 817809.00
LAB.V income_statement (annual, 2023-09-30) — Normalized EBITDA: -1259200.00
LAB.V income_statement (annual, 2023-09-30) — Normalized Income: -783609.12
LAB.V cash_flow (annual, 2023-09-30) — Operating Cash Flow: -476106.00
LAB.V income_statement (annual, 2023-09-30) — Operating Income: -1293120.00
LAB.V income_statement (annual, 2023-09-30) — Operating Revenue: 0.00
LAB.V balance_sheet (annual, 2023-09-30) — Ordinary Shares Number: 170009979.00
LAB.V balance_sheet (annual, 2023-09-30) — Other Equity Interest: 4597023.00
LAB.V income_statement (annual, 2023-09-30) — Other Gand A: 387053.00
LAB.V income_statement (annual, 2023-09-30) — Other Income Expense: 330509.00
LAB.V income_statement (annual, 2023-09-30) — Other Non Operating Income Expenses: 346509.00
LAB.V income_statement (annual, 2023-09-30) — Other Operating Expenses: 551224.00
LAB.V balance_sheet (annual, 2023-09-30) — Other Properties: 39812719.00
LAB.V balance_sheet (annual, 2023-09-30) — Other Short Term Investments: 0.00
LAB.V balance_sheet (annual, 2023-09-30) — Payables And Accrued Expenses: 999317.00
LAB.V balance_sheet (annual, 2023-09-30) — Prepaid Assets: 77831.00
LAB.V income_statement (annual, 2023-09-30) — Pretax Income: -962611.00